Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial

Abstract Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with a poor prognosis. Therapeutic options for patients with advanced ACC who have failed standard treatments are limited. Single-agent immunotherapy as a second-line treatment has shown unsatisfactory clinical outcomes. This p...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yu-Chun Zhu, Zhi-Gong Wei, Jing-Jing Wang, Yi-Yan Pei, Jing Jin, Dong Li, Zhi-Hui Li, Zhe-Ran Liu, Yu Min, Rui-Dan Li, Li Yang, Ji-Yan Liu, Qiang Wei, Xing-Chen Peng
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2024-11-01
Цуврал:	Nature Communications
Онлайн хандалт:	https://doi.org/10.1038/s41467-024-54661-9
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!